InteRNA's mission is to translate new, proprietary microRNA (miRNA) molecules and its miRNA discovery technologies into clinically and commercially successful therapeutic and companion-diagnostic products. The company’s primary focus is to unravel the role of its proprietary miRNAs in cancer.
InteRNA Technologies was incorporated in 2006 by Aglaia Oncology Fund and has established close relationships with the research groups of its founders Edwin Cuppen, PhD, and Eugene Berezikov, PhD, of the Hubrecht Institute (Utrecht, the Netherlands), leading scientific groups in the field of miRNA research.

Web: www.interna-technologies.com